<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04825418</url>
  </required_header>
  <id_info>
    <org_study_id>BETHLeHAM</org_study_id>
    <nct_id>NCT04825418</nct_id>
  </id_info>
  <brief_title>Beneficial Effect of Hypothermia Plus Hemicraniectomy Compared With Hemicraniectomy</brief_title>
  <official_title>Beneficial Effect of Therapeutic Hypothermia Plus Hemicraniectomy Compared With Hemicraniectomy Alone in Patients With Malignant Cerebral Infarction (BETHLeHAM Study) - Prospective, Open, Single-arm, Multicenter Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bard Medical Division C.R. Bard Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study safety and feasibility of mild therapeutic hypothermia after decompressive&#xD;
      hemicraniectomy compared with hemicraniectomy alone in patients with malignant cerebral&#xD;
      infarction&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current clinical trial is an investigator-initiated one, and it is conducted under the&#xD;
      multi-center, single arm, open-label, prospective design. The subject meeting&#xD;
      inclusion/exclusion criteria will be assigned to treatment group.&#xD;
&#xD;
      The subjects of treatment group should be initiated hypothermia therapy as soon as possible&#xD;
      after surgery (less than 6 hours). It can be duration at least 72 hours according to subject&#xD;
      status. Also process of recovery temperature period will be allowed within 20-40 hours. After&#xD;
      6 month, 12 month of the onset of symptom, mRS score are measured. This is followed by&#xD;
      closure of clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rankin Scale</measure>
    <time_frame>1 year after treatment</time_frame>
    <description>Functional outcome at 1 year modified Rankin Scale of 0 to 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 month, 1 year after treatment</time_frame>
    <description>Mortality at 6 month, 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>6 month after treatment</time_frame>
    <description>6 month modified Rankin Scale of 0 to 4</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Hypothermia</condition>
  <arm_group>
    <arm_group_label>Therapeutic Hypothermia Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapeutic hypothermia using surface cooling device (Arctic Sun) Decompressive Hemicraniectomy care based on international guidelines except therapeutic hypothermia using surface cooling device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artic Sun</intervention_name>
    <description>Induction phase A. Temperature using by esophageal or bladder thermometer. B. Application of a surface cooling device (Arctic Sun) C. Target temperature: 35 ± 0.5 °C D. Induction should be initiated as soon as possible after surgery (less than 6 hours)&#xD;
Maintain phase A. Maintain duration : at least 72 hours and duration can be prolonged according to patient's clinical status B. Use the bedside shivering assessment scale (BSAS) and anti-shivering protocol C. Neuromuscular blocker can be used according to the discretion of the attending physician D. Lung-protective ventilation strategies including low-tidal volume are recommended E. Prophylactic antibiotics can be used to prevent pneumonia during hypothermia&#xD;
Rewarming phase A. Rewarming rate: 0.05 - 0.1 ℃/hr (about 20 - 40 hours) to 37 ℃</description>
    <arm_group_label>Therapeutic Hypothermia Group</arm_group_label>
    <other_name>Therapeutic Hypothermia Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A. Written informed consent obtained from the patient or his/her legally acceptable&#xD;
        representative B. Acute ischemic stroke within middle cerebral artery or internal carotid&#xD;
        artery occlusion&#xD;
&#xD;
          -  Regardless of anterior cerebral artery (ACA) or posterior cerebral artery (PCA)&#xD;
             involvement C. Patients of both sexes aged ≥ 19 years and ≤ 82 years D. NIHSS score ≥&#xD;
             15 points, NIHSS loss of consciousness 1a score ≥ 1 point E. Patients with proximal&#xD;
             cerebral arterial occlusion (such as middle cerebral or internal carotid artery) F.&#xD;
             Unilateral ischemic lesion of at least 2/3 of the middle cerebral artery (MCA)&#xD;
             territory involving basal ganglia confirmed by computed tomography (CT) or magnetic&#xD;
             resonance imaging (MRI)&#xD;
&#xD;
          -  Decided to perform decompressive hemicraniectomy within 48 hours after symptom onset -&#xD;
             Onset time was defined as the time when patients were lastly seen normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A. Premorbid modified Rankin Scale (mRS) score ≥ 2 B. Presence of other type of brain&#xD;
        lesions including traumatic brain injury, contralateral or infratentorial infarct.&#xD;
&#xD;
        C. Absence of bilateral pupillary reflex D. Known bleeding disorder or coagulopathy E.&#xD;
        Sepsis F. End stage malignant disease G. Pregnancy or during breast feeding H. Life&#xD;
        expectancy less than 3 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moon-ku Han</last_name>
    <phone>82-31-787-7464</phone>
    <email>mkhan@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Han-gil Jeong</last_name>
    <email>han.g.jeong@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moon-Ku Han</name>
      <address>
        <city>Seongnam-si</city>
        <state>Bundang/kyeonggido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Moon-ku Han</last_name>
      <phone>82-31-787-7464</phone>
      <email>mkhan@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 28, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>therapeutic hypothermia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

